Filing Analysis
aTyr Pharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 7, 2026.
📋 Key Facts
- Report date: August 7, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding financial results.
aTyr Pharma has finalized the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. effective July 30, 2026. While this ends a partnership, it results in the reversion of exclusive Japanese development and commercialization rights for efzofitimod back to the Company.
🚩 Red Flags
- Loss of a strategic partner (Kyorin Pharmaceutical Co., Ltd.) which may impact funding or regional expertise/distribution in Japan.
📋 Key Facts
- Termination date for the Kyorin Agreement: July 30, 2026.
- Kyorin terminated the agreement without cause on May 12, 2026.
- Exclusive rights to develop and commercialize efzofitimod in Japan have reverted to aTyr Pharma.
- aTyr Pharma now holds global development and commercialization rights for efzofitimod.
aTyr Pharma received a notification from Nasdaq granting an additional 180-day extension until November 30, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share. The company failed to meet the initial compliance deadline of June 2, 2026.
🚩 Red Flags
- Failure to regain compliance by the initial 180-day deadline.
- Explicit mention of a potential reverse stock split to artificially inflate share price for compliance.
- Risk of delisting if compliance is not met by November 30, 2026.
📋 Key Facts
- The company received a deficiency notice on December 4, 2025, because the bid price closed below $1.00 for 30 consecutive business days.
- The initial compliance deadline was June 2, 2026.
- Nasdaq granted an extension until November 30, 2026, to regain compliance.
- Compliance requires a minimum closing bid price of $1.00 for at least 10 consecutive business days.
- The company has explicitly notified Nasdaq of its intention to cure the deficiency via a reverse stock split if necessary.
aTyr Pharma filed an 8-K to furnish an investor presentation dated June 2026. The company intends to use these materials for meetings with investors, stockholders, and analysts.
📋 Key Facts
- The filing date is June 1, 2026.
- The company is providing a corporate presentation (Exhibit 99.1) for use at investor conferences and meetings.
- The materials are being 'furnished' rather than 'filed' under Section 18 of the Securities Exchange Act of 1934.
aTyr Pharma, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made through a standard Item 2.02 filing, furnishing a press release as an exhibit.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 15, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
aTyr Pharma announced a significant pivot in its clinical development strategy for efzofitimod following a Type C meeting with the FDA. The company will initiate a new Phase 3 study with a narrowed patient population, increased dosing frequency, and enhanced safety monitoring for anti-synthetase syndrome.
🚩 Red Flags
- The requirement for a new Phase 3 study indicates that previous trial data (EFZO-FIT) was insufficient for an immediate NDA filing.
- The FDA mandated enhanced safety surveillance for the potential development of anti-synthetase syndrome, suggesting a specific safety concern.
- The company is narrowing its target patient population to a subset (restrictive lung disease) based on post-hoc analysis of 44 patients from a previous study.
📋 Key Facts
- Preliminary cash, cash equivalents, and investments totaled approximately $68.3 million as of March 31, 2026.
- The company plans to submit a new Investigational New Drug (IND) application in June 2026 for a Phase 3 study in pulmonary sarcoidosis.
- The new Phase 3 trial will target approximately 372 patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease (FVC ≤ 80%).
- Dosing frequency for the 5.0 mg/kg cohort will increase from once every four weeks to once every three weeks.
- The primary endpoint is the change from baseline in Forced Vital Capacity (FVC) at week 48.
aTyr Pharma, Inc. announced its financial results for the fiscal year ended December 31, 2025, through a press release issued on March 5, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1 to the filing.
- The filing was signed by Jill M. Broadfoot, Chief Financial Officer.
aTyr Pharma, Inc. received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until June 2, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price sustained below $1.00 (Penny stock territory)
- Potential requirement for a reverse stock split to regain compliance
📋 Key Facts
- Received Nasdaq deficiency notice on December 4, 2025.
- Reason: Bid price closed below $1.00 for the last 30 consecutive business days (Nasdaq Rule 5550(a)(2)).
- Compliance Deadline: June 2, 2026 (180-day grace period).
- Requirement to cure: Maintain a minimum closing bid price of at least $1.00 for 10 consecutive business days.
- Potential remedy mentioned: A reverse stock split may be required to qualify for a second compliance period if the first is not met.
aTyr Pharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing a press release with financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
aTyr Pharma announced that its Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis failed to meet its primary endpoint of reducing mean daily oral corticosteroid (OCS) dose. While the company reported positive nominal findings in secondary endpoints like KSQ-Lung scores, the failure of the primary objective is a significant clinical setback.
🚩 Red Flags
- Failure of primary endpoint in a Phase 3 clinical trial is a major negative catalyst for biotech companies.
- All secondary efficacy data (KSQ-Lung, FVC) are reported as 'nominal' because the hierarchical statistical testing was not triggered by the primary failure.
📋 Key Facts
- Phase 3 EFZO-FIT™ study failed to meet its primary endpoint: change from baseline in mean daily OCS dose at week 48 (p=0.3313).
- Mean daily OCS dose for 5.0 mg/kg efzofitimod was 2.79 mg vs. 3.52 mg for placebo.
- Secondary endpoint KSQ-Lung score showed improvement for 5.0 mg/kg group (p=0.0479), but these are nominal findings due to the primary failure.
- Responder analysis for patients achieving complete steroid withdrawal with improved KSQ-Lung scores was positive (29.5% vs 14.4%, p=0.0199).
- The company plans to engage with the FDA to determine a path forward based on these results.
This is an amendment (8-K/A) to a previously filed report intended to correct a clerical error in the SEC EDGAR submission header. The company is correcting the tagging from Item 2.06 (Material Impairments) back to the correct Item 2.02 (Results of Operations and Financial Condition).
📋 Key Facts
- The filing is an Amendment No. 1 to a report filed on August 7, 2025.
- The original submission was incorrectly tagged as Item 2.06 (Material Impairments) due to administrative error.
- The purpose of the amendment is to re-tag the report correctly under Item 2.02 and Item 9.01.
- No changes were made to the actual disclosure text or financial data in the original report.
aTyr Pharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes Exhibit 99.1 containing the press release of financial results
- Signed by Jill M. Broadfoot, Chief Financial Officer
aTyr Pharma, Inc. filed an 8-K to furnish its quarterly earnings press release for the three months ended March 31, 2025.
📋 Key Facts
- The filing is a standard disclosure of financial results under Item 2.02.
- Reporting period: Three months ended March 31, 2025.
- Filing date: May 7, 2025.
- The press release containing the actual financial data is attached as Exhibit 99.1.
aTyr Pharma, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 1, 2025. Shareholders approved an amendment to the 2015 Stock Plan and elected two Class I directors.
📋 Key Facts
- Annual Meeting held on May 1, 2025.
- Stockholders approved an amendment to the 2015 Stock Option and Incentive Plan to increase the maximum number of shares available for issuance by 5,000,000 (new total: 15,719,300).
- The term for incentive stock options was extended until February 26, 2035.
- Two Class I directors, Paul Schimmel, Ph.D. and Sara L. Zaknoen, M.D., were elected to hold office until the 2028 annual meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Shareholder voting results: Total shares entitled to vote = 88,858,612; Shares present/represented = 69,286,552.
aTyr Pharma, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 13, 2025
- Reporting period: Year ended December 31, 2024
- The filing is a standard announcement of annual financial results via Exhibit 99.1.
aTyr Pharma, Inc. has entered into an amendment to its existing Open Market Sale Agreement with Jefferies LLC to increase the aggregate offering amount of common stock available for sale via an at-the-market (ATM) program.
🚩 Red Flags
- Increased dilution risk: The expansion of an ATM program allows for continuous issuance of new equity, which can dilute existing shareholders.
📋 Key Facts
- Amendment No. 1 to the Sales Agreement was executed on December 23, 2024.
- The company previously sold approximately $65.0 million in shares under the original April 22, 2022 agreement.
- The amendment allows for the sale of 'Additional Shares' up to an unspecified amount (to be determined by prospectus supplements).
- Sales will be conducted via at-the-market (ATM) offerings pursuant to a Form S-3 registration statement.
- Jefferies LLC serves as the sales agent/principal.
aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors as a Class II director, effective December 10, 2024. The company also amended and restated its Non-Employee Director Compensation Policy.
📋 Key Facts
- Eric Benevich appointed to the Board of Directors on December 10, 2024.
- Benevich will serve as a Class II director until the 2026 annual meeting or successor election.
- The Company amended and restated its Non-Employee Director Compensation Policy (Exhibit 99.1).
- Mr. Benevich was granted an option to purchase 100,000 shares of common stock at the Dec 10, 2024 closing price.
- Stock options vest in equal monthly installments over a three-year period subject to continued service.
aTyr Pharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024 via a press release.
📋 Key Facts
- The filing was made on November 7, 2024.
- The report pertains to Item 2.02: Results of Operations and Financial Condition.
- Financial results for the quarter ended September 30, 2024 were released via Exhibit 99.1.
aTyr Pharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes Exhibit 99.1, which contains the full press release of financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
aTyr Pharma announced the successful completion of patient enrollment for its global pivotal Phase 3 EFZO-FIT study evaluating efzofitimod for pulmonary sarcoidosis. The trial exceeded enrollment targets and is expected to release topline data in Q3 2025.
📋 Key Facts
- Completed enrollment in the Phase 3 EFZO-FIT clinical trial.
- Trial enrolled 268 patients across 85 centers in 9 countries.
- Enrollment exceeded the company's initial target.
- Topline data readout is expected in the third quarter of 2025.
aTyr Pharma, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 22, 2024. All proposals were approved, including the election of two Class III directors and an amendment to the 2015 Stock Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 22, 2024; all shareholder proposals were approved.
- Stockholders approved an amendment to the 2015 Stock Option and Incentive Plan, increasing the maximum number of shares available for issuance from 7,713,670 to 10,713,670 (an increase of 3,000,000 shares).
- The term of the 2015 Stock Plan was extended until February 28, 2034.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- EFZO-FIT Phase 3 clinical trial enrollment is expected to complete in Q2 2024, with final dosing potentially occurring in July 2024.
aTyr Pharma, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2024. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Report date: May 2, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes Exhibit 99.1, which is the official press release containing financial results.
- Signed by Jill M. Broadfoot, Chief Financial Officer.
aTyr Pharma, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal notice that the company's annual earnings press release has been issued.
📋 Key Facts
- Reporting date: March 14, 2024
- Period covered: Fiscal year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 detailing financial results.